2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $4.93, for a total transaction of $25,350,607.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
2seventy bio Price Performance
Shares of TSVT opened at $4.95 on Friday. The company has a 50 day moving average of $2.76 and a two-hundred day moving average of $3.69. 2seventy bio, Inc. has a twelve month low of $2.29 and a twelve month high of $5.99. The company has a market cap of $255.36 million, a price-to-earnings ratio of -2.66 and a beta of 1.73.
Institutional Trading of 2seventy bio
Several large investors have recently made changes to their positions in the business. Erste Asset Management GmbH acquired a new position in shares of 2seventy bio in the 3rd quarter valued at about $25,000. China Universal Asset Management Co. Ltd. acquired a new position in 2seventy bio in the fourth quarter valued at approximately $32,000. BNP Paribas Financial Markets purchased a new stake in 2seventy bio in the 4th quarter worth approximately $35,000. ProShare Advisors LLC acquired a new stake in shares of 2seventy bio during the 4th quarter worth approximately $48,000. Finally, Raymond James Financial Inc. purchased a new position in shares of 2seventy bio during the 4th quarter valued at approximately $52,000. 93.90% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
View Our Latest Stock Report on 2seventy bio
2seventy bio Company Profile
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than 2seventy bio
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Pros And Cons Of Monthly Dividend Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Short Selling – The Pros and Cons
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.